Chai Discovery

Chai Discovery, backed by OpenAI, builds molecular structure-prediction models for antibody and small-molecule design. Biotech and pharma partners use its Chai-1 and Chai-2 platforms for de novo design. It released Chai-1 weights and code in September 2024 and reported wet-lab-validated antibody designs reaching pharma partners in 2026.

Ecosystem functionOne of very few biology labs whose model outputs have been validated in physical experiments rather than only in silico.

Business modelBiotech partnerships and licensing